- Home
- ISRG vs NVS Comparison
ISRG vs NVS Comparison
Compare ISRG & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRG
- NVS
- Stock Information
- Founded
- ISRG 1995
- NVS 1895
- Country
- ISRG United States
- NVS Switzerland
- Employees
- ISRG N/A
- NVS N/A
- Industry
- ISRG Medical/Dental Instruments
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- ISRG Health Care
- NVS Health Care
- Exchange
- ISRG Nasdaq
- NVS Nasdaq
- Market Cap
- ISRG 193.0B
- NVS 230.5B
- IPO Year
- ISRG 2000
- NVS 1991
- Fundamental
- Price
- ISRG $524.43
- NVS $97.08
- Analyst Decision
- ISRG Buy
- NVS Hold
- Analyst Count
- ISRG 21
- NVS 6
- Target Price
- ISRG $532.45
- NVS $121.25
- AVG Volume (30 Days)
- ISRG 1.3M
- NVS 1.1M
- Earning Date
- ISRG 01-21-2025
- NVS 01-31-2025
- Dividend Yield
- ISRG N/A
- NVS 3.89%
- EPS Growth
- ISRG 46.29
- NVS 130.53
- EPS
- ISRG 6.22
- NVS 8.58
- Revenue
- ISRG $7,866,900,000.00
- NVS $49,940,000,000.00
- Revenue This Year
- ISRG $16.63
- NVS $10.04
- Revenue Next Year
- ISRG $16.89
- NVS $4.55
- P/E Ratio
- ISRG $84.35
- NVS $11.02
- Revenue Growth
- ISRG 14.83
- NVS 8.92
- 52 Week Low
- ISRG $320.26
- NVS $92.35
- 52 Week High
- ISRG $556.23
- NVS $120.92
- Technical
- Relative Strength Index (RSI)
- ISRG 41.97
- NVS 27.93
- Support Level
- ISRG $539.03
- NVS $97.69
- Resistance Level
- ISRG $547.19
- NVS $99.67
- Average True Range (ATR)
- ISRG 11.79
- NVS 1.01
- MACD
- ISRG -3.59
- NVS -0.18
- Stochastic Oscillator
- ISRG 20.60
- NVS 10.97
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.